Cargando…

The disease sites of female genital cancers of BRCA1/2-associated hereditary breast and ovarian cancer: a retrospective study

Disease sites of female genital tract cancers of BRCA1/2-associated hereditary breast and ovarian cancer (HBOC) are less understood than non-hereditary cancers. We aimed to elucidate the disease site distribution of genital cancers in women with the germline BRCA1 and BRCA2 pathogenic variants (BRCA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitamura, Takashi, Sekine, Masayuki, Arai, Masami, Shibata, Yuka, Kato, Momoko, Yokoyama, Shiro, Yamashita, Hiroko, Watari, Hidemichi, Yabe, Ichiro, Nomura, Hiroyuki, Enomoto, Takayuki, Nakamura, Seigo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856749/ https://www.ncbi.nlm.nih.gov/pubmed/33531027 http://dx.doi.org/10.1186/s12957-021-02151-3

Ejemplares similares

Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy
por: Sekine, Masayuki, et al.
Publicado: (2022)

Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan
por: Arai, Masami, et al.
Publicado: (2017)

Correction: Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan
por: Arai, Masami, et al.
Publicado: (2018)

Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X
por: Yoshida, Reiko, et al.
Publicado: (2019)

BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art
por: Sekine, Masayuki, et al.
Publicado: (2021)

High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan
por: Yamauchi, Hideko, et al.
Publicado: (2018)

Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome
por: Kaneyasu, Tomoko, et al.
Publicado: (2020)

Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location
por: Sekine, Masayuki, et al.
Publicado: (2021)

Lymphadenectomy can be omitted for low-risk endometrial cancer based on preoperative assessments
por: Mitamura, Takashi, et al.
Publicado: (2014)

Practice of Hereditary ATTR Amyloidosis in Non-endemic Areas of Japan
por: Matsushima, Masaaki, et al.
Publicado: (2022)

Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study
por: Zhai, Tianyue, et al.
Publicado: (2023)

Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2
por: Samuel, David, et al.
Publicado: (2022)

Hereditary and non-hereditary branches of family eligible for BRCA test: cancers in other sites
por: Digennaro, M., et al.
Publicado: (2017)

P18/Stathmin1 is regulated by miR-31 in ovarian cancer in response to taxane
por: Hassan, Mohamed Kamel, et al.
Publicado: (2015)

BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome
por: Ewald, Ingrid Petroni, et al.
Publicado: (2016)

Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes
por: Toss, Angela, et al.
Publicado: (2015)

Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting Clusterin improves response to paclitaxel
por: Hassan, Mohamed K, et al.
Publicado: (2011)

Germline PRDM1 Variant rs2185379 in Long-Term Recurrence-Free Survivors of Advanced Ovarian Cancer
por: Mitamura, Takashi, et al.
Publicado: (2022)

Clinicopathological and ultrasound characteristics of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ikejima, Kengo, et al.
Publicado: (2023)

Correction: Clinicopathological and ultrasound characteristics of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ikejima, Kengo, et al.
Publicado: (2023)

Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families
por: NOVAKOVIĆ, SRDJAN, et al.
Publicado: (2012)

Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer
por: Buleje, Jose, et al.
Publicado: (2017)

CHEK2 contribution to hereditary breast cancer in non-BRCA families
por: Desrichard, Alexis, et al.
Publicado: (2011)

Hereditary Breast Cancer in Latvia: Mutation Analysis of the BRCA1 Gene
por: Tihomirova, L., et al.
Publicado: (1999)

Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden
por: Wendt, Camilla, et al.
Publicado: (2015)

The role of BRCA1/2 in hereditary and familial breast and ovarian cancers
por: Hawsawi, Yousef M., et al.
Publicado: (2019)

Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups
por: Todo, Yukiharu, et al.
Publicado: (2016)

Adjuvant chemotherapy for early-stage cervical cancer
por: Asano, Hiroshi, et al.
Publicado: (2016)

Inappropriate Metacognitive Status Increases State Anxiety in Genetic Counseling Clients
por: Shibata, Yuka, et al.
Publicado: (2022)

Oncological Outcomes After Okabayashi-Kobayashi Radical Hysterectomy for Early and Locally Advanced Cervical Cancer
por: Sakuragi, Noriaki, et al.
Publicado: (2020)

Hereditary Susceptibility to Breast Cancer: Significance of Age of Onset in Family History and Contribution of BRCA1 and BRCA2
por: Frank, Thomas S., et al.
Publicado: (1999)

Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family
por: Liao, Ying, et al.
Publicado: (2020)

Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer
por: Garber, Haven R., et al.
Publicado: (2022)

Chemotherapy and molecular targeting therapy for recurrent cervical cancer
por: Tsuda, Naotake, et al.
Publicado: (2016)

Multivariate survival analysis of the patients with recurrent endometrial cancer
por: Odagiri, Tetsuji, et al.
Publicado: (2011)

Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants
por: Momozawa, Yukihide, et al.
Publicado: (2022)

Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients
por: Jarhelle, Elisabeth, et al.
Publicado: (2019)

BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk
por: Kwiatkowski, Fabrice, et al.
Publicado: (2015)

Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA
por: Piombino, Claudia, et al.
Publicado: (2020)

Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer
por: Vietri, Maria Teresa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h9ckk9rqh6bq5f9d24t609srrv